Skip to main content
Clinical Trials/NCT07572656
NCT07572656CompletedNot Applicable

Comparison of the Efficacy of Intravenous Labetalol and Intravenous Hydralazine for the Treatment of Hypertension in Patients With Severe Preeclampsia.

Muhammad Aamir Latif1 site in 1 country132 target enrollmentStarted: May 1, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
132
Locations
1

Study Overview

Brief Summary

Due to limited data regarding preeclampsia from the local population, the debate is still ongoing in the study setting. Hence, the current study was planned to compare the efficacy of labetalol and hydralazine for the treatment of hypertension in patients with severe preeclampsia.

Detailed Description

As preeclampsia is associated with high perinatal mortality and morbidity, the choice of a better antihypertensive in pregnancy is still debatable. The findings of this study would help evaluate the more efficacious drug between intravenous labetalol and intravenous hydralazine in the management of severe preeclampsia. Based on this empirical evidence, practical recommendations can be developed for routine practice guidelines regarding the optimal drug choice between the two for treating severe preeclampsia and eventually to reduce perinatal mortality and morbidity for both the mother and fetus.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
20 Years to 35 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pregnant women
  • Both primiparous and multiparous women
  • Aged 20-35 years
  • Gestational age ≥20weeks (assessed on last menstrual period)
  • With severe preeclampsia

Exclusion Criteria

  • Known allergy to hydralazine or labetalol
  • Deranged liver function tests due to any other cause
  • Women with pre-existing hypertension systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg
  • Patients receiving more than one antihypertensive drug since admission
  • Women with chronic renal failure

Investigators

Sponsor
Muhammad Aamir Latif
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Muhammad Aamir Latif

Research Consultant

RESnTEC, Institute of Research

Study Sites (1)

Loading locations...

Similar Trials